# KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

> **NCT06099821** · PHASE2 · RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 39 (estimated)

## Conditions studied

- Digestive System Cancers

## Interventions

- **DRUG:** KN046
- **DRUG:** Regorafenib
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT06099821
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-25
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2023-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06099821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06099821, "KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade". Retrieved via MORVS 2026-11-03 from https://api.morvs.ai/clinical/NCT06099821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*